GSK plc (NYSE:GSK) released headline results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin) combination for relapsed or refractory multiple myeloma.
The 302-participant trial evaluated Blenrep, combined with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment.
The trial met its primary endpoint of progression-free survival (PFS) at a pre-specified interim analysis and was unblinded early based on the recommendation by an Independent Data Monitoring Committee.
The belantamab mafodotin combination significantly extended the time to disease progression or death versus the standard …